Holding(s) in Company

TR-1: NOTIFICATION   OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying   issuer
  of existing shares to which voting rights are
  attached:
ii
AstraZeneca   plc
2 Reason for the notification (please tick the   appropriate box or boxes):
An   acquisition or disposal of voting rights X
An   acquisition or disposal of qualifying financial instruments which may result   in the acquisition of shares already issued to which voting rights are   attached
An   acquisition or disposal of instruments with similar economic effect to   qualifying financial instruments
An   event changing the breakdown of voting rights
Other   (please specify):
3. Full name of person(s) subject to   the
  notification obligation:
iii
The Capital Group Companies, Inc.
4. Full name of shareholder(s)
 
(if different from 3.):iv
See Schedule A
5. Date of the transaction and date   on
  which the threshold is crossed or
  reached:
  v
1   June 2015
6. Date on which issuer notified: 2   June 2015
7. Threshold(s) that is/are crossed   or
  reached:
vi,   vii
Below 3%
8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of
  shares

 
if   possible using
  the ISIN CODE
Situation previous
  to the triggering
  transaction
Resulting situation   after the triggering transaction
Number
  of
  Shares
Number
  of
  Voting
  Rights
Number
  of shares
Number of voting
  rights
% of voting rights x
Direct Direct xi Indirect xii Direct Indirect
Ordinary   Shares(ISIN:   GB0009895292) 31,704,772 31,704,772    30,437,552 2.4088%
ADRs   (ISIN:   US0463531089) 7,433,161 7,433,161        7,435,104 0.5884%
B: Qualifying Financial Instruments
Resulting situation   after the triggering transaction
Type of financial
  instrument
Expiration
  date
xiii
Exercise/
  Conversion Period
xiv
Number of voting
  rights that may be
  acquired if the
  instrument is
  exercised/ converted.
% of voting
  rights
C: Financial Instruments with   similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation   after the triggering transaction
Type of financial
  instrument
Exercise price Expiration date xvii Exercise/
  Conversion period
xviii
Number of voting   rights instrument refers to % of voting rights xix, xx
Nominal Delta
Total (A+B+C)
Number of voting   rights Percentage of   voting rights
37,872,656 2.9972%
9. Chain of controlled undertakings   through which the voting rights and/or the
  financial instruments are effectively held, if applicable:
xxi
See Schedule A
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy   holder will cease
  to hold:
12. Date on which proxy holder will   cease to hold
  voting rights:

  13. Additional information:
 
 
14. Contact name:
15. Contact telephone number:

                                                       Schedule A

As of 1 June 2015

AstraZeneca PLC

Number   of Shares Percent   of Outstanding
The   Capital Group Companies, Inc. (“CG”) holdings 37,872,656 2.997%
Holdings by CG   Management Companies and Funds:
Capital   Guardian Trust Company 5,512,014 0.436%
Capital   International Limited 165,100 0.013%
Capital   International Sàrl 154,992 0.012%
Capital   International, Inc. 72,900 0.006%
Capital   Research and Management Company 31,967,650 2.530%

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links